|
|
||||||||

Divisions of
* Viral Products and
Cytokine Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland
Correspondence: Hana Golding, Division of Viral Products, Center for Biologics and Evaluation and Research, Building 29B, Room 4NN04, HFM 454, Bethesda, MD 20892. E-mail:
The chemokine receptor CXCR4 is a primary coreceptor for the HIV-1 virus. The predicted molecular weight (MW) of glycosylated CXCR4 is 4547 kDa. However, immunoblots of whole cell lysates from human lymphocytes, monocytes, macrophages, and the Jurkat T-lymphocyte line revealed multiple MW isoforms of CXCR4. Three of the bands could be precipitated by anti-CXCR4 monoclonal antibodies (101 and 47 kDa) or coprecipitated with CD4 (62 kDa). Expression of these isoforms was enhanced by infection with a recombinant vaccinia virus encoding CXCR4. In immunoblots of two-dimensional gels, antiubiquitin antibodies reacted with the 62-kDa CXCR4 species from monocytes subsequent to coprecipitation with anti-CD4 antibodies. Culturing of monocytes and lymphocytes with lactacystin enhanced the amount of the 101-kDa CXCR4 isoform in immunoblots by three- to sevenfold. In lymphocytes, lactacystin also increased cell-surface expression of CXCR4, which correlated with enhanced fusion with HIV-1 envelope-expressing cells. Similar increases in the intensity of the 101-kDa isoform were seen after treatment with the lysosomal inhibitors monensin and ammonium chloride. Antiubiquitin antibodies reacted with multiple proteins above 62 kDa, which were precipitated with anti-CXCR4 antibodies. Our data indicate that ubiquitination may contribute to CXCR4 heterogeneity and suggest roles for proteasomes and lysosomes in the constitutive turnover of CXCR4 in primary human cells.
Key Words: monocytes lymphocytes chemokine receptor HIV-1
This article has been cited by other articles:
![]() |
P. I. Lobo, K. H. Schlegel, C. E. Spencer, M. D. Okusa, C. Chisholm, N. Mchedlishvili, A. Park, C. Christ, and C. Burtner Naturally Occurring IgM Anti-Leukocyte Autoantibodies (IgM-ALA) Inhibit T Cell Activation and Chemotaxis J. Immunol., February 1, 2008; 180(3): 1780 - 1791. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Reggeti, C. Ackerley, and D. Bienzle CD134 and CXCR4 expression corresponds to feline immunodeficiency virus infection of lymphocytes, macrophages and dendritic cells J. Gen. Virol., January 1, 2008; 89(1): 277 - 287. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Melar, D. E. Ott, and T. J. Hope Physiological Levels of Virion-Associated Human Immunodeficiency Virus Type 1 Envelope Induce Coreceptor-Dependent Calcium Flux J. Virol., February 15, 2007; 81(4): 1773 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Holland, M. Kochetkova, C. Akekawatchai, M. Dottore, A. Lopez, and S. R. McColl Differential functional activation of chemokine receptor CXCR4 is mediated by g proteins in breast cancer cells. Cancer Res., April 15, 2006; 66(8): 4117 - 4124. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zaitseva, T. Romantseva, J. Manischewitz, J. Wang, D. Goucher, and H. Golding Increased CXCR4-dependent HIV-1 fusion in activated T cells: role of CD4/CXCR4 association J. Leukoc. Biol., December 1, 2005; 78(6): 1306 - 1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Balabanian, B. Lagane, J. L. Pablos, L. Laurent, T. Planchenault, O. Verola, C. Lebbe, D. Kerob, A. Dupuy, O. Hermine, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12 Blood, March 15, 2005; 105(6): 2449 - 2457. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-Z. Decrion, A. Varin, J.-M. Estavoyer, and G. Herbein CXCR4-mediated T cell apoptosis in human immunodeficiency virus infection J. Gen. Virol., June 1, 2004; 85(6): 1471 - 1478. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Kuhmann, P. Pugach, K. J. Kunstman, J. Taylor, R. L. Stanfield, A. Snyder, J. M. Strizki, J. Riley, B. M. Baroudy, I. A. Wilson, et al. Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor J. Virol., March 15, 2004; 78(6): 2790 - 2807. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |